Colorectal Cancer Liver Metastases: Multimodal Therapy

Berk Aykut; Michael E Lidsky

doi:10.1016/j.soc.2022.07.009

Colorectal Cancer Liver Metastases: Multimodal Therapy

Surg Oncol Clin N Am. 2023 Jan;32(1):119-141. doi: 10.1016/j.soc.2022.07.009. Epub 2022 Nov 3.

Authors

Berk Aykut¹, Michael E Lidsky²

Affiliations

¹ Department of Surgery, Division of Surgical Oncology, Duke University Medical Center, Box 3966, 10 Bryan Searle Drive, 466G Seeley G. Mudd Building, Durham, NC 27710, USA. Electronic address: https://twitter.com/BerkAykutMD.
² Department of Surgery, Division of Surgical Oncology, Duke University Medical Center, Box 3966, 10 Bryan Searle Drive, 466G Seeley G. Mudd Building, Durham, NC 27710, USA. Electronic address: Michael.Lidsky@duke.edu.

PMID: 36410912
DOI: 10.1016/j.soc.2022.07.009

Abstract

Despite a steady decline in incidence and mortality rates, colorectal cancer (CRC) remains the second most common cancer diagnosis in women and the third most common in men worldwide. Notably, the liver is recognized as the most common site of CRC metastasis, and metastases to the liver remain the primary driver of disease-specific mortality for patients with CRC. Although hepatic resection is the backbone of curative-intent treatment, management of CRLM has become increasingly multimodal during the last decade and includes the use of downstaging chemotherapy, ablation techniques, and locoregional therapy, each of which are reviewed herein.

Keywords: Chemotherapy; Colorectal cancer; Liver metastasis; Perioperative chemotherapy; Randomized controlled trial; Surgery.

Publication types

Review

MeSH terms

Colorectal Neoplasms* / therapy
Combined Modality Therapy
Female
Humans
Liver Neoplasms* / therapy
Male